Noncalcified coronary plaque in systemic lupus erythematosus

Adnan Kiani, Jens Vogel-Claussen, Laurence S. Magder, Michelle Petri

Research output: Contribution to journalArticle

Abstract

Objective. To study noncalcified coronary plaque (NCP) in systemic lupus erythematosus (SLE). Methods. Sixty-four-slice coronary multidetector computed tomography (MDCT) was performed in 39 consecutive patients with SLE. MDCT scans were evaluated semiquantitatively by a radiologist using dedicated software. The presence or absence of NCP in each coronary artery was assessed. Patients with mixed plaque (calcified and noncalcified portions) were included in the NCP group. Results. The patient group was 90% women, 64% Caucasian, 31% African American, 5% other; mean age 50.5 ± 9.6 years. Fifty-four percent (21/39) had NCP. Seventy-six percent (16/21) of those with NCP also had coronary calcium (range 0.7 to 1264.1 Agatston units). In univariate analysis, NCP was associated with age (p = 0.01), current nonsteroidal antiinflammatory drug (NSAID) use (p = 0.04), hormone replacement therapy (p = 0.02), current use of immunosuppressive drugs (p = 0.02), current low serum C3 level (p = 0.07), current physician's global assessment of activity (PGA; p = 0.05), and low-density lipoprotein cholesterol (p = 0.04). NCP was not associated with other risk factors for atherosclerosis, including total serum cholesterol, high sensitivity C-reactive protein, and lipoprotein(a). Conclusion. Unlike coronary calcium, which is not associated with SLE activity measures or with active serologies, NCP is more common in patients with SLE with current, 3-, and 6-month activity by PGA. NCP was also associated with the need for current NSAID or immunosuppressive therapy. NCP is an important part of the total atherosclerotic burden in SLE.

Original languageEnglish (US)
Pages (from-to)579-584
Number of pages6
JournalJournal of Rheumatology
Volume37
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Systemic Lupus Erythematosus
Prostaglandins A
Multidetector Computed Tomography
Immunosuppressive Agents
Anti-Inflammatory Agents
Pharmaceutical Preparations
Calcium
Lipoprotein(a)
Hormone Replacement Therapy
Serology
Serum
African Americans
C-Reactive Protein
LDL Cholesterol
Atherosclerosis
Coronary Vessels
Software
Cholesterol
Physicians
Therapeutics

Keywords

  • Noncalcified coronary plaque
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Noncalcified coronary plaque in systemic lupus erythematosus. / Kiani, Adnan; Vogel-Claussen, Jens; Magder, Laurence S.; Petri, Michelle.

In: Journal of Rheumatology, Vol. 37, No. 3, 03.2010, p. 579-584.

Research output: Contribution to journalArticle

Kiani, Adnan ; Vogel-Claussen, Jens ; Magder, Laurence S. ; Petri, Michelle. / Noncalcified coronary plaque in systemic lupus erythematosus. In: Journal of Rheumatology. 2010 ; Vol. 37, No. 3. pp. 579-584.
@article{322561d42b834cef9be087072a36d61a,
title = "Noncalcified coronary plaque in systemic lupus erythematosus",
abstract = "Objective. To study noncalcified coronary plaque (NCP) in systemic lupus erythematosus (SLE). Methods. Sixty-four-slice coronary multidetector computed tomography (MDCT) was performed in 39 consecutive patients with SLE. MDCT scans were evaluated semiquantitatively by a radiologist using dedicated software. The presence or absence of NCP in each coronary artery was assessed. Patients with mixed plaque (calcified and noncalcified portions) were included in the NCP group. Results. The patient group was 90{\%} women, 64{\%} Caucasian, 31{\%} African American, 5{\%} other; mean age 50.5 ± 9.6 years. Fifty-four percent (21/39) had NCP. Seventy-six percent (16/21) of those with NCP also had coronary calcium (range 0.7 to 1264.1 Agatston units). In univariate analysis, NCP was associated with age (p = 0.01), current nonsteroidal antiinflammatory drug (NSAID) use (p = 0.04), hormone replacement therapy (p = 0.02), current use of immunosuppressive drugs (p = 0.02), current low serum C3 level (p = 0.07), current physician's global assessment of activity (PGA; p = 0.05), and low-density lipoprotein cholesterol (p = 0.04). NCP was not associated with other risk factors for atherosclerosis, including total serum cholesterol, high sensitivity C-reactive protein, and lipoprotein(a). Conclusion. Unlike coronary calcium, which is not associated with SLE activity measures or with active serologies, NCP is more common in patients with SLE with current, 3-, and 6-month activity by PGA. NCP was also associated with the need for current NSAID or immunosuppressive therapy. NCP is an important part of the total atherosclerotic burden in SLE.",
keywords = "Noncalcified coronary plaque, Systemic lupus erythematosus",
author = "Adnan Kiani and Jens Vogel-Claussen and Magder, {Laurence S.} and Michelle Petri",
year = "2010",
month = "3",
doi = "10.3899/jrheum.090824",
language = "English (US)",
volume = "37",
pages = "579--584",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Noncalcified coronary plaque in systemic lupus erythematosus

AU - Kiani, Adnan

AU - Vogel-Claussen, Jens

AU - Magder, Laurence S.

AU - Petri, Michelle

PY - 2010/3

Y1 - 2010/3

N2 - Objective. To study noncalcified coronary plaque (NCP) in systemic lupus erythematosus (SLE). Methods. Sixty-four-slice coronary multidetector computed tomography (MDCT) was performed in 39 consecutive patients with SLE. MDCT scans were evaluated semiquantitatively by a radiologist using dedicated software. The presence or absence of NCP in each coronary artery was assessed. Patients with mixed plaque (calcified and noncalcified portions) were included in the NCP group. Results. The patient group was 90% women, 64% Caucasian, 31% African American, 5% other; mean age 50.5 ± 9.6 years. Fifty-four percent (21/39) had NCP. Seventy-six percent (16/21) of those with NCP also had coronary calcium (range 0.7 to 1264.1 Agatston units). In univariate analysis, NCP was associated with age (p = 0.01), current nonsteroidal antiinflammatory drug (NSAID) use (p = 0.04), hormone replacement therapy (p = 0.02), current use of immunosuppressive drugs (p = 0.02), current low serum C3 level (p = 0.07), current physician's global assessment of activity (PGA; p = 0.05), and low-density lipoprotein cholesterol (p = 0.04). NCP was not associated with other risk factors for atherosclerosis, including total serum cholesterol, high sensitivity C-reactive protein, and lipoprotein(a). Conclusion. Unlike coronary calcium, which is not associated with SLE activity measures or with active serologies, NCP is more common in patients with SLE with current, 3-, and 6-month activity by PGA. NCP was also associated with the need for current NSAID or immunosuppressive therapy. NCP is an important part of the total atherosclerotic burden in SLE.

AB - Objective. To study noncalcified coronary plaque (NCP) in systemic lupus erythematosus (SLE). Methods. Sixty-four-slice coronary multidetector computed tomography (MDCT) was performed in 39 consecutive patients with SLE. MDCT scans were evaluated semiquantitatively by a radiologist using dedicated software. The presence or absence of NCP in each coronary artery was assessed. Patients with mixed plaque (calcified and noncalcified portions) were included in the NCP group. Results. The patient group was 90% women, 64% Caucasian, 31% African American, 5% other; mean age 50.5 ± 9.6 years. Fifty-four percent (21/39) had NCP. Seventy-six percent (16/21) of those with NCP also had coronary calcium (range 0.7 to 1264.1 Agatston units). In univariate analysis, NCP was associated with age (p = 0.01), current nonsteroidal antiinflammatory drug (NSAID) use (p = 0.04), hormone replacement therapy (p = 0.02), current use of immunosuppressive drugs (p = 0.02), current low serum C3 level (p = 0.07), current physician's global assessment of activity (PGA; p = 0.05), and low-density lipoprotein cholesterol (p = 0.04). NCP was not associated with other risk factors for atherosclerosis, including total serum cholesterol, high sensitivity C-reactive protein, and lipoprotein(a). Conclusion. Unlike coronary calcium, which is not associated with SLE activity measures or with active serologies, NCP is more common in patients with SLE with current, 3-, and 6-month activity by PGA. NCP was also associated with the need for current NSAID or immunosuppressive therapy. NCP is an important part of the total atherosclerotic burden in SLE.

KW - Noncalcified coronary plaque

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=77949731490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949731490&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090824

DO - 10.3899/jrheum.090824

M3 - Article

C2 - 20110529

AN - SCOPUS:77949731490

VL - 37

SP - 579

EP - 584

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -